FINANCINGS

Adaptimmune Therapeutics plc closed its registered direct offering of its American depositary shares following its entry into a definitive agreement with Matrix Capital Management Co. LP to purchase $42 million of the shares.

Axovant Sciences Ltd. priced its underwritten public offering with gross proceeds expected to be approximately $125 million.

Bioblast Pharma Ltd. canceled its underwritten public offering of securities due to adverse market conditions.

Biohaven Pharmaceutical Holding Co. Ltd. filed an S-1 with the SEC for an IPO of up to $100 million.

Catalyst Biosciences Inc. closed its public offering of units for gross proceeds of $20.7 million.

Cirius Therapeutics Inc. (previously Octeta Therapeutics LLC) completed a series A financing of up to $40 million.

Dicerna Pharmaceuticals Inc. closed its stock purchase transaction for the sale of redeemable convertible preferred stock to a syndicate of investors under which the company received gross proceeds of $70 million.

Frequency Therapeutics Inc. has closed a $32 million series A financing.

Lyndra Inc. has closed a $23 million series A financing.

Ovid Therapeutics Inc. filed an S-1 with the SEC indicating its intention to raise up to $86.25 million in an IPO.

Sorrento Therapeutics Inc. priced its public offering of 23.6 million shares at $2 each for gross proceeds of about $47.3 million

Tocagen Inc. priced its IPO of 8.5 million shares at $10 apiece, the low end of its proposed range, to raise $85 million in gross proceeds.

Urogen Pharma Ltd. has filed its form F-1 with the SEC to raise up to $50 million in an IPO.

DEALS

Cancer Genetics Inc. has been selected by Effector Therapeutics Inc. to provide clinical biomarker services for its lead product candidate eFT508, an oral small-molecule inhibitor of MNK1 and 2.

Dermata Therapeutics LLC signed an exclusive global license agreement with Villani Inc. for its natural sponge product to be developed by Dermata as a potential treatment for a variety of skin diseases.

Lead Discovery Center GmbH, Max Planck Innovation GmbH, and Sotio A.S. have signed a collaboration and license agreement providing Sotio with exclusive rights to an oncology program addressing a novel target in tumor metabolism.

Mundipharma International Ltd. inked a strategic partnership with Kolon Life Science Inc. to market Invossa, Kolon's cell-medicated gene therapy for osteoarthritis.

Peptidream Inc. inked a potential $1.15 billion multitarget collaboration with Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson. Peptidream will use its peptide discovery platform system to identify macrocyclic/constrained peptides against metabolic and cardiovascular targets of interest.

Shire plc is collaborating with Patientslikeme to support development of a patient-centered, real-world health learning system that expands understanding of patient health and disease.

Sumitomo Dainippon Pharma Co. Ltd. said it concluded a license agreement with Bukwang Pharmaceutical Co. Ltd. for the development and sales in Korea of lurasidone hydrochloride, an atypical antipsychotic agent.

. . . AND MORE

Active Biotech AB said the FDA granted orphan drug designation for its investigational agent, tasquinimod, an immunomodulatory, antimetastatic and anti-angiogenic compound for the treatment of multiple myeloma.

Japan's pharmaceutical market is still the most attractive in the Asia-Pacific region and only second to the U.S. globally, according to a recent report by BMI Research.

Oncomed Pharmaceuticals Inc.'s notch-targeting cancer candidate, demcizumab, failed to outperform standard-of-care gemcitabine and Abraxane on the trial's primary endpoint of median progression-free survival in a phase II pancreatic cancer trial.